Lol. If you focus on preclinical data while ignoring clinical data, then this will be our last conversation
Still on the HER-Vaxx train, huh?
Simple, important question for you to answer:
If HER-Vaxx was so good, then why have IMU not done a head-to-head with Herceptin in a phase 2 trial for gastric cancer patients?
Moreover, Enhertu is outperforming Herceptin, so why aren't they challenging that with a head to head?
The reason they have not is because HER-Vaxx is not good enough.
Why are you citing preclinical data when the clinical data is all right there for CF33? CHECKvacc and CF33-hNIS are where you should be looking. If it was so sensitive at low doses in cell models, why is that not translating to the clinic. Here is the dosing protocol for T-Vec (approved) and CF33 in patients. Looks like CF33 is not 100 to 1000 times more potent. You would want to hope your runway runs deeep!
onCARlytics heading down the same path. Without the addition of PBMC, onCARlytics and Blinatumomab achieve a stable disease in a mouse model. With the so far inadequate efficacy of CF33 in patients, your program is shaping up terribly.
The B cell platform is dead. CF33 forms a backbone for 2 of your other programs. Limited activity for CF33 while injecting the drug
DIRECTLY INTO PATIENTS CANCERS is beginning to erode the foundation of IMU, that's why they bought Azer Zel. If you can't generate more than 1 CR in a sweep of patients and cancer types, IMU will be trading at cash in the near future.
